August 15, 2022 6:13 a.m. EDT
(24/7 MARKET NEWS) Unity Biotech (NASDAQ: UBX) is following through its big Friday move in this morning’s premarket session, trading at $1.53, up 22 cents (+16.79%), on 3.63 million premarket shares traded.
After announcing positive data in Phase 2 BEHOLD study of UBX1325, in patients with diabetic macular edema, and reporting second quarter 2022 financial results, Unity Biotech gapped up to open Friday’s regular session at $1.83 and hit a high of $1.85, drifted down throughout the day to close at $1.31, a gain of $0.4599 (+54.10%), on 94,545,656 shares
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to https://www.247marketnews.com/terms-disclaimer/ for further information.
